Phase 1b and Dose-Expansion Study of GSK3326595, a PRMT5 Inhibitor as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cancers
乔垣结衣
15天前
32
20
已完结
1. 系统已在2025-09-26 14:06:58对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/j.annonc.2025.08.3757
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0923753425046964
其他信息:
出版社: Elsevier BV
作者: M.M. Gounder; P. Martin-Romano; A. Italiano; L.L. Siu; P.A. Cassier; G.S. Falchook; I.S. Lossos; D.W. Rasco; J.F. Hilton; M.A. McKean; F.L. Opdam; J. Strauss; M. De Jonge; J.S.P. Vermaat; T. Crossman; M. Zajac; A. Tarkar; F. Gonzalez Carreras; B.E. Kremer; O. Barbash; S. Segal; R. Parasrampuria; S. Postel-Vinay
